Acadian Asset Management LLC Boosts Stake in Personalis, Inc. (NASDAQ:PSNL)

Acadian Asset Management LLC raised its position in shares of Personalis, Inc. (NASDAQ:PSNL) by 6.7% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 1,057,956 shares of the company’s stock after acquiring an additional 66,128 shares during the period. Acadian Asset Management LLC owned approximately 2.04% of Personalis worth $1,237,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently added to or reduced their stakes in PSNL. Jacobs Levy Equity Management Inc. lifted its stake in shares of Personalis by 144.7% during the first quarter. Jacobs Levy Equity Management Inc. now owns 821,657 shares of the company’s stock worth $1,224,000 after purchasing an additional 485,822 shares in the last quarter. ARK Investment Management LLC lifted its stake in shares of Personalis by 4.9% during the second quarter. ARK Investment Management LLC now owns 6,361,886 shares of the company’s stock worth $7,443,000 after purchasing an additional 296,413 shares in the last quarter. Howland Capital Management LLC lifted its stake in shares of Personalis by 392.8% during the first quarter. Howland Capital Management LLC now owns 211,118 shares of the company’s stock worth $315,000 after purchasing an additional 168,274 shares in the last quarter. Bruce & Co. Inc. lifted its stake in shares of Personalis by 100.0% during the fourth quarter. Bruce & Co. Inc. now owns 300,000 shares of the company’s stock worth $630,000 after purchasing an additional 150,000 shares in the last quarter. Finally, Quadrature Capital Ltd acquired a new position in shares of Personalis during the fourth quarter worth about $152,000. Hedge funds and other institutional investors own 61.91% of the company’s stock.

Analyst Ratings Changes

A number of research analysts have commented on PSNL shares. Needham & Company LLC boosted their price objective on Personalis from $5.50 to $7.25 and gave the stock a “buy” rating in a research note on Friday, August 16th. BTIG Research boosted their price target on Personalis from $5.50 to $7.00 and gave the stock a “buy” rating in a research note on Friday, August 16th. Finally, HC Wainwright boosted their price target on Personalis from $7.50 to $9.00 and gave the stock a “buy” rating in a research note on Monday, August 19th.

Personalis Stock Performance

NASDAQ:PSNL opened at $5.69 on Monday. Personalis, Inc. has a one year low of $0.89 and a one year high of $7.20. The business’s 50-day simple moving average is $4.10 and its 200 day simple moving average is $2.36. The stock has a market cap of $295.53 million, a price-to-earnings ratio of -2.99 and a beta of 1.91.

Personalis (NASDAQ:PSNL) last announced its quarterly earnings data on Wednesday, August 7th. The company reported ($0.24) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.34) by $0.10. Personalis had a negative return on equity of 56.87% and a negative net margin of 101.78%. The firm had revenue of $22.58 million for the quarter, compared to analysts’ expectations of $19.81 million. During the same quarter in the prior year, the firm posted ($0.50) earnings per share. On average, equities research analysts predict that Personalis, Inc. will post -1.15 EPS for the current year.

About Personalis

Personalis, Inc develops and markets advanced cancer genomic tests and analytics primarily in the United States, Europe, and the Asia-Pacific. Its tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and development of personalized cancer therapies, as well as advanced tests are used by physicians to detect cancer recurrence, monitor cancer evolution, and uncover insights for therapy selection.